Caris Life Sciences director receives 13,192-share equity grant

PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. director Phillips T. Danny received an equity award reported as 13,192 shares of Common Stock, reflected as a grant or award of restricted stock units. The award was at a stated price of $0.00 per share and increased his direct holdings to 133,060 shares. The restricted stock units vest in accordance with the applicable grant agreement.

Insider Trade Summary

Grant/Award: 13,192 shares

Grant/Award 1 txn

Insider PHILLIPS T DANNY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 133,060 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Key Figures

Shares granted: 13,192 shares Stated grant price: $0.00 per share Holdings after transaction: 133,060 shares +1 more

4 metrics

Shares granted 13,192 shares Grant or award of restricted stock units reported as Common Stock

Stated grant price $0.00 per share Price field for the 13,192-share grant transaction

Holdings after transaction 133,060 shares Total direct Common Stock holdings following the award

10b5-1 plan status Unchecked Affirmative Rule 10b5-1 checkbox is false for this filing

Key Terms

restricted stock units, grant, award, or other acquisition, Rule 10b5-1

3 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"transaction code description is Grant, award, or other acquisition"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Caris Life Sciences (CAI) report for Phillips T. Danny?

Caris Life Sciences reported that director Phillips T. Danny received a grant of 13,192 shares of Common Stock, described as an award of restricted stock units that vest under an applicable grant agreement, increasing his direct holdings to 133,060 shares.

How many Caris Life Sciences (CAI) shares does Phillips T. Danny hold after this Form 4?

Following the reported award, Phillips T. Danny directly holds 133,060 shares of Caris Life Sciences Common Stock. This reflects the addition of 13,192 shares from a grant of restricted stock units reported in the filing.

Was the Caris Life Sciences (CAI) insider award to Phillips T. Danny a market purchase or a grant?

The transaction is characterized as a grant or award acquisition, not a market purchase. The Form 4 notes an award of restricted stock units covering 13,192 shares at a stated price of $0.00 per share.

What type of equity did Phillips T. Danny receive from Caris Life Sciences (CAI)?

Phillips T. Danny received an award of restricted stock units tied to 13,192 shares of Common Stock. A footnote explains these restricted stock units vest in accordance with the applicable grant agreement.

Is the Caris Life Sciences (CAI) Form 4 transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked, indicating the reported grant of 13,192 restricted stock unit–based shares was not affirmed as executed under a Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 05:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PHILLIPS T DANNY

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		13,192(1)	A	$0	133,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)